Evolution of pneumococcal disease prevention

Learning outcomes

Upon completion of this module, participants will be able to:

• Identify the current PCVs licensed for paediatric use and differentiate their serotype coverage against pneumococcal disease
• Determine the factors that contribute to the unique epidemiology of IPD and PCV coverage estimates in Hong Kong
• Understand the current situation with serotype 3 and how PCVs may be utilised to mitigate its impacts on the population
• Summarise safety and immunogenicity findings from key clinical trials comparing various PCVs
• Learn about the existing recommendations for pneumococcal vaccinations, including the preferred vaccine schedule for PCV20 in specific countries

Topics Covered:

• Role of the nasopharyngeal microbiome in serotype replacement
• Current available PCVs and their respective serotype coverages
• PCV coverage estimates and epidemiology of IPD in Hong Kong
• Key clinical evidence on different PCVs across all age groups
• Recommendations for pneumococcal vaccinations
• Determinants of successful vaccination programmes

• How do PCV formulations impact nasopharyngeal carriage in infants and toddlers?
  https://doi.org/10.1080/14760584.2019.1627207
• Serotype distribution of pneumococcal meningitis in PCV10- and PCV13-using countries – Findings from PSERENADE:
  https://doi.org/10.3390/microorganisms9040738
• Hong Kong Centre for Health Protection Reports on IPD:
  https://www.chp.gov.hk/en/resources/29/636.html
• US Food and Drug Administration (FDA) product information for PCV20:
  https://www.fda.gov/vaccines-blood-biologics/vaccines/prevnar-20
• European Medicines Agency (EMA) product information for PCV20:
  https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-20